Al-Ola Abdallah, Associate Professor of Medicine at the University of Kansas Medical Center, shared on X:
“At the National ICE T conference, Dr. Daniel Carrizosa discussed bispecific T-cell engagers (BiTEs) in small cell lung cancer, spotlighting tarlatamab-dlle (Imdelltra) – approved in May 2024 for ES-SCLC.
A promising new frontier in immunotherapy.”
More posts featuring Al-Ola Abdallah on OncoDaily.